DQ-9
DQ-9 is a selective immunoproteasome β5i inhibitor (IC50=0.0019 μM). DQ-9 generates additional inhibitory substances via iron-mediated intracellular activation, and induces oxidative stress, carbon-centered free radicals and macromolecular damage through its artemisinin domain. DQ-9 induces apoptosis in leukemia and multiple myeloma cells. DQ-9 exhibits selective cytotoxicity against leukemia and multiple myeloma cells by elevating the labile iron pool. DQ-9 can be used in the research of hematological malignancies (leukemia, multiple myeloma, mantle cell lymphoma, acute myeloid leukemia).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2803611-81-4
- Formule: C33H46BNO8
- Masse moléculaire:595.53
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
DQ-9 (0.2-1.0 μM; 6 h) induces the accumulation of polyubiquitinated proteins in MM.1S multiple myeloma cells[1].
DQ-9 (0.1-0.5 μM; 16 h) induces G2/M phase arrest in MM.1S multiple myeloma cells, significantly upregulates p21, and exerts a stronger effect than DQ-10 (HY-18078)[1].
DQ-9 (72 h) selectively inhibits the growth of human leukemia cell lines in the NCI-60 cell panel, and exhibits stronger potency than DQ-10 in most leukemia cell lines[1].
DQ-9 (0.1-1.0 μM; 6-16 h) potently induces apoptosis in MM.1S multiple myeloma cells and HL-60 acute myeloid leukemia cells, and its pro-apoptotic activity is stronger than that of DQ-10[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MM.1S multiple myeloma cells, HL-60 acute myeloid leukemia cells
-
Concentration:0.1-1.0 μM (16 h for apoptotic markers); 0.2-1.0 μM (6 h for polyubiquitination)
-
Incubation Time:6 h (polyubiquitination); 16 h (apoptotic markers)
-
Result:Robust cleavage of PARP and Caspase-3 was detected in MM.1S cells treated with 0.5 μM DQ-9 for 6 h, and with 0.2 μM DQ-9 for 16 h.
In HL-60 cells, cleaved PARP and Caspase-3 were detected at 0.2 μM DQ-9 following 16 h of treatment.
DQ-10 required ≥2.5 μM to induce comparable apoptotic signaling.
-
Cell Line:MM.1S multiple myeloma cells
-
Concentration:0.1-0.5 μM
-
Incubation Time:16 h
-
Result:DQ-9 induced significant G2/M phase arrest in MM.1S cells, with more pronounced arrest than DQ-10 at matched concentrations (e.g., 27.1% G2/M at 0.2 μM DQ-9 vs 19.8% at 0.2 μM DQ-10).
Treatment also induced robust accumulation of the CDK inhibitor p21, with strong upregulation observed at 0.1 μM DQ-9.
Chemical Information
-
CAS No. 2803611-81-4
-
Masse moléculaire 595.53
-
Formule C33H46BNO8
-
SMILES
O=C(N[C@H](B1OC(C)(C)C(C)(C)O1)CC2=COC3=CC=CC=C23)C[C@@H]4[C@H](C)[C@]5([H])CC[C@@H](C)[C@]6([H])CC[C@@](O7)(C)OO[C@]65[C@]7([H])O4
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
DQ-9 Related Classifications
HY-183683 Related Classifications
Powered by Bioz
- DQ-9
- 2803611-81-4
- DQ9
- DQ 9
- Proteasome
- Apoptosis
- leukemia cells
- MM.1S multiple myeloma cells
- constitutive β5c subunit
- hematologic malignancies
- acute myeloid leukemia cells
- mantle cell lymphoma
- HFF-1 fibroblast cells
- immunoproteasome β5i subunit
- HL-60 acute myeloid leukemia cells
- multiple myeloma cells
- Inhibitor
- inhibitor
- inhibit